Lilly’s peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine

Peresolimab met the primary efficacy endpoint in patients with refractory rheumatoid arthritis (RA) Study evaluated a novel approach to treating patients with autoimmune diseases INDIANAPOLIS, May 18, 2023 /PRNewswire/ — The New England Journal of Medicine today published detailed…

Leave a Reply

Your email address will not be published. Required fields are marked *